Table 1a:
Cytokeratin (CKs) antibodies used in this study with frequency of positivity.
CK antibody used* | No of positive cases | No. of negative cases | Percent of positivity (%) |
---|---|---|---|
CK5/6 | 55 | 33 | 63 |
CK14 | 53 | 26 | 67 |
AE1/AE3** | 40 | 25 | 62 |
CAM5.2 | 54 | 30 | 64 |
MNF116 | 44 | 24 | 67 |
34βE12 | 15 | 22 | 41 |
CK7 | 33 | 36 | 49 |
CK8 | 17 | 10 | 63 |
CK18 | 18 | 12 | 60 |
CK17 | 9 | 1 | 80 |
CK19 | 18 | 26 | 41 |
The CKs used in this study were not uniformly tested in all cases; different combinations of CKs were used for each case;
Each pan-cytokeratin is considered as one CK antibody in this study. Other CKs including CK5, CK20 and panCK were stained in few cases only, so they were not included in this table.